NGL FINECHEM
Quarterly Results Analysis [Dec2023]
NGL FINECHEM Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹88 Cr | ₹80 Cr | ₹71 Cr | ₹74 Cr | ₹72 Cr | ₹68 Cr | ₹65 Cr | ₹84 Cr |
Expenses | ₹74 Cr | ₹66 Cr | ₹61 Cr | ₹61 Cr | ₹62 Cr | ₹59 Cr | ₹63 Cr | ₹74 Cr |
Operating Income | ₹14 Cr | ₹14 Cr | ₹10 Cr | ₹13 Cr | ₹10 Cr | ₹9 Cr | ₹2 Cr | ₹11 Cr |
Other Income | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹3 Cr | ₹3 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr |
Depreciation | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹1 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr |
Profit Before Tax | ₹14 Cr | ₹14 Cr | ₹10 Cr | ₹12 Cr | ₹9 Cr | ₹6 Cr | ₹1 Cr | ₹9 Cr |
Profit After Tax | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹9 Cr | ₹6 Cr | ₹5 Cr | ₹1 Cr | ₹7 Cr |
EPS | ₹16.24 | ₹16.96 | ₹13.77 | ₹15.09 | ₹10.50 | ₹7.56 | ₹0.84 | ₹11.12 |
Industry Peers & Returns | 1W | 1M | 1Y |
NGL FINECHEM | 4.4% | -1.1% | 73.9% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
NGL FINECHEM Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 9.70 % |
Y-o-Y | 22.27 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹88 Cr | 9.70 | |
Sep2023 | ₹80 Cr | 12.86 | |
Jun2023 | ₹71 Cr | -3.86 | |
Mar2023 | ₹74 Cr | 2.72 | |
Dec2022 | ₹72 Cr | 6.23 | |
Sep2022 | ₹68 Cr | 3.78 | |
Jun2022 | ₹65 Cr | -22.38 | |
Mar2022 | ₹84 Cr | - |
NGL FINECHEM Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -0.72 % |
Y-o-Y | 41.32 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹14 Cr | -0.72 | |
Sep2023 | ₹14 Cr | 41.63 | |
Jun2023 | ₹10 Cr | -23.97 | |
Mar2023 | ₹13 Cr | 32.20 | |
Dec2022 | ₹10 Cr | 7.27 | |
Sep2022 | ₹9 Cr | 326.68 | |
Jun2022 | ₹2 Cr | -79.70 | |
Mar2022 | ₹11 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -9.47 % |
Y-o-Y | 15.62 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 15.77% | -9.47 | |
Sep2023 | 17.42% | 25.50 | |
Jun2023 | 13.88% | -20.96 | |
Mar2023 | 17.56% | 28.74 | |
Dec2022 | 13.64% | 0.96 | |
Sep2022 | 13.51% | 310.64 | |
Jun2022 | 3.29% | -73.83 | |
Mar2022 | 12.57% | - |
NGL FINECHEM Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -4.24 % |
Y-o-Y | 54.70 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹10 Cr | -4.24 | |
Sep2023 | ₹10 Cr | 23.17 | |
Jun2023 | ₹9 Cr | -8.77 | |
Mar2023 | ₹9 Cr | 43.77 | |
Dec2022 | ₹6 Cr | 38.92 | |
Sep2022 | ₹5 Cr | 799.61 | |
Jun2022 | ₹1 Cr | -92.44 | |
Mar2022 | ₹7 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -12.70 % |
Y-o-Y | 26.50 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 11.41 % | -12.70 | |
Sep2023 | 13.07 % | 9.19 | |
Jun2023 | 11.97 % | -5.15 | |
Mar2023 | 12.62 % | 39.91 | |
Dec2022 | 9.02 % | 30.91 | |
Sep2022 | 6.89 % | 761.25 | |
Jun2022 | 0.8 % | -90.21 | |
Mar2022 | 8.17 % | - |
NGL FINECHEM Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -4.25 % |
Y-o-Y | 54.67 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹16.24 | -4.25 | |
Sep2023 | ₹16.96 | 23.17 | |
Jun2023 | ₹13.77 | -8.75 | |
Mar2023 | ₹15.09 | 43.71 | |
Dec2022 | ₹10.5 | 38.89 | |
Sep2022 | ₹7.56 | 800.00 | |
Jun2022 | ₹0.84 | -92.45 | |
Mar2022 | ₹11.12 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD